Quince Therapeutics Inc (QNCX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to...

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to...

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to...

Quince Therapeutics Launches Scientific Advisory Board

World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company’s lead Phase 3 asset, new...

Form 8-K - Current report

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a...

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a...

Form 4 - Statement of changes in beneficial ownership of securities